DOCSLIB.ORG

Hepatic Issues and Complications Associated with Inflammatory Bowel Disease: a Clinical Report from the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hepatic Issues and Complications Associated with Inflammatory Bowel Disease: a Clinical Report from the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees SOCIETY STATEMENT Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees ÃLawrence J. Saubermann, yMark Deneau, zRichard A. Falcone, §Karen F. Murray, jjSabina Ali, ôRohit Kohli, #Udeme D. Ekong, ÃÃPamela L. Valentino, yyAndrew B. Grossman, yyzzElizabeth B. Rand, ÃÃMaureen M. Jonas, ôShehzad A. Saeed, and §§Binita M. Kamath ABSTRACT Hepatobiliary disorders are common in patients with inflammatory bowel epatobiliary disorders are common in patients with inflamma- disease (IBD), and persistent abnormal liver function tests are found in H tory bowel disease (IBD), and persistent abnormal liver enzyme approximately 20% to 30% of individuals with IBD. In most cases, the cause tests are found in approximately 20% to 30% of individuals with IBD of these elevations will fall into 1 of 3 main categories. They can be as a (1–4). In most cases, the cause of these elevations will fall into 1 of 3 result of extraintestinal manifestations of the disease process, related to main categories. They can be a result of extraintestinal manifestations medication toxicity, or the result of an underlying primary hepatic disorder of the disease process, related to medication toxicity, or the result of an unrelated to IBD. This latter possibility is beyond the scope of this review underlying primary hepatic disorder unrelated to IBD (Table 1). This article, but does need to be considered in anyone with elevated liver function latter possibility is beyond the scope of this clinical report, but does tests. This review is provided as a clinical summary of some of the major need to be considered in anyone with elevated liver enzyme levels. This hepatic issues that may occur in patients with IBD. report is provided as a clinical summary of some of the major hepatic issues that may manifest in patients with IBD. Key Words: autoimmune hepatitis, Crohn disease, hepatitis, inflammatory bowel disease, primary sclerosing cholangitis, ulcerative colitis Extraintestinal Associations of Inflammatory (JPGN 2017;64: 639–652) Bowel Disease Primary Sclerosing Cholangitis Primary sclerosing cholangitis (PSC) is a chronic, progress- Received October 21, 2016; accepted December 8, 2016. ive, cholestatic liver disease. It is characterized by inflammation From the ÃDivision of Pediatric Gastroenterology and Nutrition, Golisano and fibrosis of the entire biliary tree, with multifocal bile duct Children’s Hospital, University of Rochester, Rochester, NY, the strictures. PSC is rare in the general pediatric population, with an y Division of Pediatric Gastroenterology, University of Utah, Salt Lake incidence and prevalence of 0.2 and 1.5 cases per 100,000 children, City, the zDivision of Pediatric General and Thoracic Surgery, Cincin- nati Children’s Hospital Medical Center, Cincinnati, OH, the §Division respectively (5). The majority of PSC cases appear concurrently of Pediatric Gastroenterology and Hepatology, Seattle Children’s Hos- with IBD, particularly ulcerative colitis (UC) (6,7). The proportion pital, Seattle, WA, the jjDivision of Pediatric Gastroenterology, Stanford of patients with IBD with PSC varies and is most often reported to Children’s Health, Palo Alto, CA, the ôDivision of Pediatric Gastro- be 4% or less (6,8,9). Study designs vary greatly and may under- enterology, Hepatology, and Nutrition, Cincinnati Children’s Hospital estimate the true prevalence, however. Rates of PSC in IBD are 10% Medical Center, Cincinnati, OH, the #Section of Pediatric Gastroenter- to 25% in series that are population based, that have longer follow- ology and Hepatology, Yale University School of Medicine, New Haven, up (10), or where groups of patients are screened with liver biopsy CT, the ÃÃDivision of Gastroenterology, Hepatology, and Nutrition, and/or cholangiography regardless of symptoms (11,12). Boston Children’s Hospital, Harvard Medical School, Boston, MA, the Intestinal inflammation in a patient with PSC may represent a yyDivision of Gastroenterology, Hepatology, and Nutrition, Children’s Hospital of Philadelphia, the zzPerelman School of Medicine, University unique phenotype of IBD, termed PSC-IBD (7). PSC-IBD is charac- of Pennsylvania, Philadelphia, PA, and the §§Division of Gastroenter- terized by more frequent pancolitis with rectal sparing, and a higher ology, Hepatology, and Nutrition, The Hospital for Sick Children, incidence of backwash ileitis compared with UC (7). Patients with University of Toronto, Toronto, Canada. Crohn disease (CD) and PSC are more likely to have Crohn colitis Address correspondence and reprint requests to Lawrence J. Saubermann, (7,13–15). The IBD activity of PSC-IBD may be less severe (15,16), MD, FACG, AGAF, Chief, Division of Pediatric Gastroenterology and with a lower rate of colectomy (17). Patients with PSC-IBD are, Nutrition, Director, Pediatric Clinical Research Office, Golisano however, at much greater risk of colorectal carcinoma (18), and have Children’s Hospital, University of Rochester Medical Center, 601 a worsened overall survival compared with patients with traditional Elmwood Ave, Box 667, Rochester, NY 14642 UC (7). In addition, pouchitis is more common in PSC-IBD after (e-mail: [email protected]). colectomy with ileal pouch-anal anastomosis surgery (19,20). The authors report no conflicts of interest. Copyright # 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Diagnosis Gastroenterology, Hepatology, and Nutrition. The diagnosis of PSC is based on a cholestatic serum DOI: 10.1097/MPG.0000000000001492 biochemical profile with characteristic changes on liver histology JPGN Volume 64, Number 4, April 2017 639 Copyright © ESPGHAL and NASPGHAN. All rights reserved. Saubermann et al JPGN Volume 64, Number 4, April 2017 TABLE 1. Hepatobiliary issues to consider in patients with inflamma- years of PSC diagnosis (3). The 5-year survival with the native liver tory bowel disease is approximately 80% (5,25,26). PSC is one of the most important sources of morbidity and mortality for pediatric patients with IBD. Extraintestinal manifestations: In a population-based study of more than 600 pediatric patients with Immune-related: IBD followed for a median of approximately 6 years, 8 deaths or Primary sclerosing cholangitis liver transplants were related to PSC, 2 deaths were from hema- Autoimmune hepatitis tologic malignancy, and only 1 death was secondary to compli- Autoimmune sclerosing cholangitis cations of intestinal disease (colorectal cancer [CRC]) (5). Thrombotic disorders: Portal vein thrombosis Treatment Venous thromboembolism Treatment of PSC is mainly supportive and palliative. Bile Hepatic vein thrombosis acids and antimicrobials have received the most attention and Medication Toxicity: clinical use, and are discussed below. Several medicines have been Glucocorticoids shown to improve liver biochemistry with prolonged therapy, but no Sulfasalazine drug has been proven to alter the natural history of the disease. Liver Thiopurines transplantation (LT) remains the only option for progressive PSC. Methotrexate Pediatric data on ursodeoxycholic acid (ursodiol) are limited. Anti-TNFs Small series have shown improvement in liver biochemistries, but Underlying disorder: data are lacking on histology, cholangiography, and survival out- Cholelithiasis comes (25–27). Currently a prospective trial of ursodiol treatment Viral Hepatitis for PSC in children is underway and is recruiting subjects (Clin- Transplant issues icalTrials.gov NCT01088607). Ursodiol has been extensively stu- IgG4 cholangiopathy died in adult PSC, and doses of 17 to 23 mg Á kgÀ1 Á dayÀ1 will Granulomatous hepatitis generally lead to improvement in liver biochemistries, but patient Primary biliary cirrhosis survival has not improved (25–27). Conversely, concerns over Hepatic amyloidosis adverse effects from high-dose ursodiol have been raised. A Nonalcoholic fatty liver disease/steatohepatitis randomized trial of ursodiol (28–30 mg Á kgÀ1 Á dayÀ1) for adults with PSC was terminated early due to clinical deterioration of TNF ¼ tumor necrosis factor. patients in the treatment arm (28). Ursodiol use was associated with a 2-fold risk of death or transplant and a 4-fold risk of CRC (28). One expert group now specifically recommends against the use of (fibro-obliterative cholangitis, periductal fibrosis), and/or cholan- ursodiol for PSC in adults in general, although it remains widely giography (multifocal bile duct strictures and segmental dilations) prescribed in moderate doses (21). Based on these adult data, high- typically initially imaged by magnetic resonance cholangiopan- dose ursodiol (28–30 mg Á kgÀ1 Á dayÀ1) should be avoided creatography (MRCP), and confirmed by endoscopic retrograde in children. cholangiopancreatography (ERCP) if needed (21). Liver involve- Limited anecdotal evidence supports the use of oral vanco- ment of PSC progresses independent of the bowel involvement in mycin as a potential treatment of pediatric PSC. A case series of 14 IBD (7,22). In fact, patients who undergo total colectomy for IBD pediatric patients treated with oral vancomycin described complete continue to have PSC activity. Immunosuppressive therapy for IBD normalization in ALT, GGT, and erythrocyte sedimentation rate in does not appear to affect the progression of PSC. Clinicians must all noncirrhotic PSC patients (4). In contrast, during prospective consider PSC even
Load more

Recommended publications
  • Print This Article
    International Surgery Journal Lew D et al. Int Surg J. 2021 May;8(5):1575-1578 http://www.ijsurgery.com pISSN 2349-3305 | eISSN 2349-2902 DOI: https://dx.doi.org/10.18203/2349-2902.isj20211831 Case Report Acute gangrenous appendicitis and acute gangrenous cholecystitis in a pregnant patient, a difficult diagnosis: a case report David Lew, Jane Tian*, Martine A. Louis, Darshak Shah Department of Surgery, Flushing Hospital Medical Center, Flushing, New York, USA Received: 26 February 2021 Accepted: 02 April 2021 *Correspondence: Dr. Jane Tian, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Abdominal pain is a common complaint in pregnancy, especially given the physiological and anatomical changes that occur as the pregnancy progresses. The diagnosis and treatment of common surgical pathologies can therefore be difficult and limited by the special considerations for the fetus. While uncommon in the general population, concurrent or subsequent disease processes should be considered in the pregnant patient. We present the case of a 36 year old, 13 weeks pregnant female who presented with both acute appendicitis and acute cholecystitis. Keywords: Appendicitis, Cholecystitis, Pregnancy, Pregnant INTRODUCTION population is rare.5 Here we report a case of concurrent appendicitis and cholecystitis in a pregnant woman. General surgeons are often called to evaluate patients with abdominal pain. The differential diagnosis list must CASE REPORT be expanded in pregnant woman and the approach to diagnosing and treating certain diseases must also be A 36 year old, 13 weeks pregnant female (G2P1001) adjusted to prevent harm to the fetus.
    [Show full text]
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • Acute Cholecystitis View Online At
    Acute Cholecystitis View online at http://pier.acponline.org/physicians/diseases/d642/d642.html Module Updated: 2013-02-20 CME Expiration: 2016-02-20 Author Badri Man Shrestha, MS, MPhil, MD, FRCS Table of Contents 1. Prevention .........................................................................................................................2 2. Diagnosis ..........................................................................................................................4 3. Consultation ......................................................................................................................8 4. Hospitalization ...................................................................................................................11 5. Therapy ............................................................................................................................12 6. Patient Education ...............................................................................................................16 7. Follow-up ..........................................................................................................................17 References ............................................................................................................................19 Glossary................................................................................................................................23 Tables ...................................................................................................................................25
    [Show full text]
  • Topical Budesonide for Treating Giant Rectal Pseudopolyposis
    ANTICANCER RESEARCH 25: 2961-2964 (2005) Topical Budesonide for Treating Giant Rectal Pseudopolyposis CHARALAMPOS PILICHOS1, ATHENA PREZA1, MARIA DEMONAKOU2, DIMITRIOS KAPATSORIS1 and CONSTANTINOS BOURAS1 1First Department of Internal Medicine and 2Department of Pathology, Sismanogleion Hospital, Athens, Greece Abstract. Pseudopolyps are a frequent finding in the course of Case Report inflammatory bowel disease. They are non-neoplastic lesions resulting from a regenerative and healing process that leaves A 45-year-old male patient was admitted to our service in July inflamed colonic mucosa in polypoid configuration. Data about 2002 for acute rectal bleeding. All laboratory tests were their management is lacking. "Giant" pseudopolyps can be normal, except an increase of aminotransferases level (>10 N) mistaken for adenocarcinomas and, as they rarely regress with and a serological profile consistent with acute hepatitis B or a medical management alone, a surgical resection is often required. flare of chronic hepatitis B (HbsAg +, HbsAb –, HbeAg –, A case of giant pseudopolyposis treated non-surgically, in a patient HbeAb +, HbcAb-IgM +). The patient underwent lower with concomitant ulcerative colitis and chronic hepatitis B, is gastro-intestinal endoscopy and multiple biopsies were taken reported, representing a co-morbidity complicating an eventual from a bulky rectal mass lesion (Figure 1). Histological study conservative treatment. The clinical implementation of topical revealed alterations compatible with inflammatory bowel budesonide was originally tested, resulting in clinical, endoscopic disease (IBD) with no dysplasia (Figure 2). Because of the and histological remission. Budesonide seems a promising therapy atypical macroscopic features and the high suspicion of rectal for IBD, particularly when a comorbidity with viral hepatitis exist.
    [Show full text]
  • Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D
    PRACTICE PARAMETERS Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D. • Scott R. Steele, M.D. • Mika Varma, M.D. • Sharon Dykes, M.D. Robert Cima, M.D. • W. Donald Buie, M.D. • Janice Rafferty, M.D. Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons the most common surgical indication for UC. Whether is dedicated to assuring high-quality patient care it is secondary to an inability to control symptoms, poor Tby advancing the science, prevention, and manage- quality of life, risks/side effects of chronic medical therapy ment of disorders and diseases of the colon, rectum, and (especially long-term corticosteroids), noncompliance, or anus. The Standards Committee is composed of Society growth failure, patients may opt for surgery in the elective members who are chosen because they have demonstrat- or semielective setting.3 Complete removal of all the poten- ed expertise in the specialty of colon and rectal surgery. tial disease-bearing tissue is theoretically curative in UC. This Committee was created to lead international efforts Operative options include an abdominal colectomy or total in defining quality care for conditions related to the co- proctocolectomy with either a permanent end ileostomy or lon, rectum, and anus. This is accompanied by develop- surgical construction of a “new” rectum through an IPAA ing Clinical Practice Guidelines based on the best available that restores GI continuity.4,5 All these procedures may evidence. These guidelines are inclusive, and not prescrip- be performed by using open or minimally invasive tech- tive.
    [Show full text]
  • Autoimmune Hepatitis
    Page 1 of 5 Autoimmune Hepatitis Autoimmune hepatitis is an uncommon cause of chronic hepatitis (persistent liver inflammation). The cause is not known. If left untreated, the inflammation causes cirrhosis (scarring of the liver). However, with treatment, the outlook for people with this condition is very good. Treatment is usually with steroids and other medicines which suppress inflammation. What does the liver do? The liver is in the upper right part of the abdomen. It has many functions which include: Storing glycogen (fuel for the body) which is made from sugars. When required, glycogen is broken down into glucose which is released into the bloodstream. Helping to process fats and proteins from digested food. Making proteins that are essential for blood to clot (clotting factors). Processing many medicines which you may take. Helping to remove or process alcohol, poisons and toxins from the body. Making bile which passes from the liver to the gut down the bile duct. Bile breaks down the fats in food so that they can be absorbed from the bowel. What is autoimmune hepatitis? Hepatitis means inflammation of the liver. There are many causes of hepatitis. For example, alcohol excess and infections with various viruses are the common causes of hepatitis. Autoimmune hepatitis is an uncommon cause of chronic hepatitis. Chronic means that the inflammation is persistent or long-term. The chronic inflammation gradually damages the liver cells, which can result in serious problems. What causes autoimmune hepatitis? Page 2 of 5 The cause is not clear. It is thought to be an autoimmune disease. Our immune system normally defends us against infection from bacteria, viruses and other germs.
    [Show full text]
  • Epigastric Pain and Hyponatremia Due to Syndrome of Inappropriate
    CLINICAL CASE EDUCATION ,0$-ǯ92/21ǯ$35,/2019 Epigastric Pain and Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion and Delirium: The Forgotten Diagnosis Tawfik Khoury MD, Adar Zinger MD, Muhammad Massarwa MD, Jacob Harold MD and Eran Israeli MD Department of Gastroenterology and Liver Disease, Hadassah–Hebrew University Medical Center, Ein Kerem Campus, Jerusalem, Israel Complete blood count, liver enzymes, alanine aminotrans- KEY WORDS: abdominal pain, gastroparesis, hyponatremia, neuropathy, ferase (ALT), aspartate transaminase (AST), gamma glutamyl porphyria, syndrome of inappropriate antidiuretic hormone transpeptidase (GGT), alkaline phosphatase (ALK), total bili- secretion (SIADH) rubin, serum electrolytes, and creatinine level were all normal. IMAJ 2019; 21: 288–290 C-reactive protein (CRP) and amylase levels were normal as well. The combination of atypical abdominal pain and mild epigastric tenderness, together with normal liver enzymes and amylase levels, excluded the diagnosis of hepatitis and pancreatitis. Although normal liver enzymes cannot dismiss For Editorial see page 283 biliary colic, the absence of typical symptoms indicative of bili- ary pathology and the normal inflammatory markers (white previously healthy 30-year-old female presented to the blood cell count and CRP) decreased the likelihood of biliary A emergency department (ED) with abdominal epigastric colic and cholecystitis, as well as an infectious gastroenteritis. pain that began 2 weeks prior to her admission. The pain Thus, the impression was that the patient’s symptoms may be was accompanied by nausea and vomiting. There were no from PUD. Since the patient was not over 45 years of age and fevers, chills, heartburn, rectal bleeding, or diarrhea. The she had no symptoms such as weight loss, dysphagia, or night pain was not related to meals and did not radiate to the back.
    [Show full text]
  • EASL Clinical Practice Guidelines: Autoimmune Hepatitisq
    Clinical Practice Guidelines EASL Clinical Practice Guidelines: Autoimmune hepatitisq ⇑ European Association for the Study of the Liver striking progress, and now patients in specialised centres have an Introduction excellent prognosis, both in respect to survival and to quality of life. Autoimmune hepatitis (AIH) was the first liver disease for which The aim of the present Clinical Practice Guideline (CPG) is to an effective therapeutic intervention, corticosteroid treatment, provide guidance to hepatologists and general physicians in the was convincingly demonstrated in controlled clinical trials. diagnosis and treatment of AIH in order to improve care for However, 50 years later AIH still remains a major diagnostic affected patients. In view of the limited data from large con- and therapeutic challenge. There are two major reasons for this trolled studies and trials, many recommendations are based on apparent contradiction: Firstly, AIH is a relatively rare disease. expert consensus. This is to some extent a limitation of this Secondly, AIH is a very heterogeneous disease. EASL-CPG, but at the same time it is its special strength: consen- Like other rare diseases, clinical studies are hampered by the sus in this guideline is based on intensive discussions of experts limited number of patients that can be included in trials. Possibly from large treatment centres. The core consensus group has and more importantly, the interest of the pharmaceutical indus- experience of over one thousand AIH patients managed person- try to develop effective specific therapies for rare diseases is lim- ally, and the recommendations have been reviewed by both the ited due to the very restricted market for such products.
    [Show full text]
  • Picquestion of the Week:3/09/09
    McKechnie Field - Spring Training Home of the Pirates PIC QUESTION OF THE WEEK: 3/09/09 Q: Why is rifaximin used in patients with pouchitis? A: Pouchitis is an inflammation of the internal pouch fashioned from small intestinal tissue during ileal pouch anal anastamosis (IPAA). This surgical procedure bypasses the large intestine and may be employed in patients with ulcerative colitis or Crohn’s disease. A temporary ileostomy is placed to allow the pouch to heal without risk of infection. IPAA is considered preferable to an ostomy for patients suffering from inflammatory bowel diseases refractory to medical treatment. The pouch serves as a collection device for waste, but permits the patient to experience regular bowel movements. It is typical for patients with an internal pouch to experience more frequent (average 6 per day) and watery bowel movements. Pouchitis is the most common complication of IPAA and widely regarded as an idiopathic disease; however, colonization by fecal bacteria may be a contributing factor. The condition occurs most commonly in the first six months following reversal of the ileostomy. Although its frequency decreases after six months, nearly 50% of patients with an IPAA will eventually experience pouchitis. Presenting symptoms include diarrhea, increased frequency of bowel movements, bleeding, abdominal pain, and fever. It can result in dehydration and, in severe cases, hospitalization. Treatment of acute pouchitis generally consists of a two-week course of antibiotic therapy with metronidazole or ciprofloxacin. Approximately 10% of patients do not respond to initial treatment and develop chronic (> 4 weeks) pouchitis. A small number of clinical trials support the potential use of rifaximin for the treatment of refractory or recurrent pouchitis.
    [Show full text]
  • Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease
    pathogens Article Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study Giuseppe Losurdo 1,2 , Andrea Iannone 1, Antonella Contaldo 1, Michele Barone 1 , Enzo Ierardi 1 , Alfredo Di Leo 1,* and Mariabeatrice Principi 1 1 Section of Gastroenterology, Department of Emergency and Organ Transplantation, University “Aldo Moro” of Bari, 70124 Bari, Italy; [email protected] (G.L.); [email protected] (A.I.); [email protected] (A.C.); [email protected] (M.B.); [email protected] (E.I.); [email protected] (M.P.) 2 Ph.D. Course in Organs and Tissues Transplantation and Cellular Therapies, Department of Emergency and Organ Transplantation, University “Aldo Moro” of Bari, 70124 Bari, Italy * Correspondence: [email protected]; Tel.: +39-080-559-2925 Received: 14 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: We performed an epidemiologic study to assess the prevalence of chronic viral hepatitis in inflammatory bowel disease (IBD) and to detect their possible relationships. Methods: It was a single centre cohort cross-sectional study, during October 2016 and October 2017. Consecutive IBD adult patients and a control group of non-IBD subjects were recruited. All patients underwent laboratory investigations to detect chronic hepatitis B (HBV) and C (HCV) infection. Parameters of liver function, elastography and IBD features were collected. Univariate analysis was performed by Student’s t or chi-square test. Multivariate analysis was performed by binomial logistic regression and odds ratios (ORs) were calculated. We enrolled 807 IBD patients and 189 controls. Thirty-five (4.3%) had chronic viral hepatitis: 28 HCV (3.4%, versus 5.3% in controls, p = 0.24) and 7 HBV (0.9% versus 0.5% in controls, p = 0.64).
    [Show full text]
  • Pouchitis in Pediatric Ulcerative Colitis: a Multicenter Study on Behalf
    Digestive and Liver Disease 51 (2019) 1551–1556 Contents lists available at ScienceDirect Digestive and Liver Disease jou rnal homepage: www.elsevier.com/locate/dld Alimentary Tract Pouchitis in pediatric ulcerative colitis: A multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition a b b c Valeria Dipasquale , Girolamo Mattioli , Serena Arrigo , Matteo Bramuzzo , d e e e Caterina Strisciuglio , Simona Faraci , Erminia Francesca Romeo , Anna Chiara Contini , f g h i a,∗ Marco Ventimiglia , Giovanna Zuin , Enrico Felici , Patrizia Alvisi , Claudio Romano a Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy b Pediatric Surgery Unit, Giannina Research Institute and Children Hospital, Genova, Italy c Pediatric Department, Gastroenterology, Digestive Endoscopy and Nutrition Unit, Institute for Maternal and Child Health, IRCCS “Burlo Garofalo”, Trieste, Italy d Department of Woman, Child and General and Specialistic Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy e Digestive Endoscopy and Surgery Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy f Inflammatory Bowel Disease Unit, “Villa Sofia-Cervello” Hospital, Palermo, Italy g Pediatric Department, University of Milano Bicocca, FMBBM, San Gerardo Hospital, Monza, Italy h Unit of Pediatrics and “Umberto Bosio” Center for Digestive Diseases, The Children Hospital, AON SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy i Pediatric Gastroenterology Unit, Maggiore Hospital, Bologna, Italy a r t i c l e i n f o a b s t r a c t Article history: Background: Data on the epidemiology and risk factors for pouchitis following restorative Received 27 April 2019 proctocolectomy and ileal pouch-anal anastomosis (IPAA) in pediatric patients with ulcerative colitis Accepted 27 June 2019 (UC) are scarce.
    [Show full text]
  • Zoonotic Diseases Fact Sheet
    ZOONOTIC DISEASES FACT SHEET s e ion ecie s n t n p is ms n e e s tio s g s m to a a o u t Rang s p t tme to e th n s n m c a s a ra y a re ho Di P Ge Ho T S Incub F T P Brucella (B. Infected animals Skin or mucous membrane High and protracted (extended) fever. 1-15 weeks Most commonly Antibiotic melitensis, B. (swine, cattle, goats, contact with infected Infection affects bone, heart, reported U.S. combination: abortus, B. suis, B. sheep, dogs) animals, their blood, tissue, gallbladder, kidney, spleen, and laboratory-associated streptomycina, Brucellosis* Bacteria canis ) and other body fluids causes highly disseminated lesions bacterial infection in tetracycline, and and abscess man sulfonamides Salmonella (S. Domestic (dogs, cats, Direct contact as well as Mild gastroenteritiis (diarrhea) to high 6 hours to 3 Fatality rate of 5-10% Antibiotic cholera-suis, S. monkeys, rodents, indirect consumption fever, severe headache, and spleen days combination: enteriditis, S. labor-atory rodents, (eggs, food vehicles using enlargement. May lead to focal chloramphenicol, typhymurium, S. rep-tiles [especially eggs, etc.). Human to infection in any organ or tissue of the neomycin, ampicillin Salmonellosis Bacteria typhi) turtles], chickens and human transmission also body) fish) and herd animals possible (cattle, chickens, pigs) All Shigella species Captive non-human Oral-fecal route Ranges from asymptomatic carrier to Varies by Highly infective. Low Intravenous fluids primates severe bacillary dysentery with high species. 16 number of organisms and electrolytes, fevers, weakness, severe abdominal hours to 7 capable of causing Antibiotics: ampicillin, cramps, prostration, edema of the days.
    [Show full text]